Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting

被引:1
|
作者
Kilpelainen, Maritta [1 ,2 ]
Hirvonen, Tuuli [1 ,2 ]
Perkonoja, Katariina [3 ]
Hirsjarvi, Samuli [4 ]
机构
[1] Turku Univ Hosp, Dept Pulm Dis, Turku 20500, Finland
[2] Univ Turku, Turku 20500, Finland
[3] Turku Univ Hosp, Hosp Dist Southwest Finland, Auria Clin Informat, Turku 20521, Finland
[4] Boehringer Ingelheim Finland Ky, Helsinki 00180, Finland
来源
MEDICINA-LITHUANIA | 2023年 / 59卷 / 02期
关键词
real-world data; interstitial lung disease; idiopathic pulmonary fibrosis; progressive pulmonary fibrosis; incidence; prevalence; IDIOPATHIC PULMONARY-FIBROSIS;
D O I
10.3390/medicina59020281
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: This single-center retrospective study was conducted to describe clinical characteristics and the disease course of patients with interstitial lung diseases (ILD). Materials and Methods: The study included adult patients with fibrosing ILD (IPF, non-IPF fibrosing ILD (F-ILD), and non-IPF progressive pulmonary fibrosis (PPF)) treated between 2014 and 2017. Patients were followed annually from the first visit until the end of the study period in 2019. Data were collected from the Turku University Hospital data lake and analyzed using descriptive statistics. Results: 591 patients formed the patient cohort: 110 had IPF, 194 F-ILD, 142 PPF, and the remaining 145 patients were uncertain, F-ILD-U, whose disease progression nature could not be confirmed by FVC measurements. There were more males in each patient group and median age of the groups was similar, although there were younger patients in the PPF, F-ILD, and F-ILD-U groups. PPF patients had more UIP pattern than F-ILD patients. Exposure-related ILDs were clearly the most found ILD diagnoses for both PPF and F-ILD, followed by unclassifiable IIP. Baseline FVC % predicted reduction in every group was moderate. Half of the patients in each group had comorbidities, and the most common were cardiovascular diseases, diabetes, sleep apnea, and chronic lower respiratory diseases; F-ILD-U patients had malignant diseases as well. IPF patients had less medications than the other groups. Glucocorticoids were the most used medication in all patient groups. More PPF and F-ILD patients remained in the follow-up than IPF and F-ILD-U patients. Similarly, mortality of F-ILD-U was the highest, followed by IPF. Evolvement of lung function, oxygen use, and number of acute hospitalizations were similar for IPF and PPF patients whereas the corresponding results were always better for F-ILD patients. Conclusions: The disease course of IPF and PPF was similar, and PPF patient amount exceeded the amount of IPF patients.
引用
下载
收藏
页数:14
相关论文
共 50 条
  • [41] Longitudinal Alignment of Disease Progression in Fibrosing Interstitial Lung Disease
    Vogl, Wolf-Dieter
    Prosch, Helmut
    Mueller-Mang, Christina
    Schmidt-Erfurth, Ursula
    Langs, Georg
    MEDICAL IMAGE COMPUTING AND COMPUTER-ASSISTED INTERVENTION - MICCAI 2014, PT II, 2014, 8674 : 97 - 104
  • [42] Clinical and demographic characteristics of patients (pts) treated with vemurafenib in real-world setting
    Sadetsky, N.
    Corvino, F.
    Surinach, A.
    Goodman, G.
    MELANOMA RESEARCH, 2016, 26 : E42 - E42
  • [43] The application of transbronchial cryobiopsy in interstitial lung disease: a prospective, multicenter, real-world study
    Chen, Xiaobo
    Li, Jing
    Luo, Fengming
    Tao, Feng
    Zhang, Xiaoju
    Wu, Youru
    Xu, Ping
    Ke, Mingyao
    Long, Fa
    Liu, Laiyu
    Lv, Liping
    Liao, Huai
    Gu, Ye
    Liu, Zhiguang
    Tan, Xiaoming
    Guo, Shuliang
    Hu, Yi
    Yang, Huaping
    Zhou, Yong
    Zhou, Hongmei
    Ye, Yongshun
    Chen, Difei
    Li, Shiyue
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (22)
  • [44] Complications of lung cancer in the clinical course of interstitial lung disease
    Noguchi, Y.
    Takei, R.
    Hayai, S.
    Oi, H.
    Yamano, Y.
    Yokoyama, T.
    Matsuda, T.
    Kataoka, K.
    Kimura, T.
    Kondoh, Y.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [45] PREVALENCE OF FIBROSING PROGRESSIVE INTERSTITIAL LUNG DISEASE IN RHEUMATOID ARTHRITIS PATIENTS
    Manfredi, A.
    Venerito, V.
    Cazzato, M.
    Gentileschi, S.
    La Corte, L.
    Iuliano, A. M.
    Cassone, G.
    Vacchi, C.
    Tomassini, C.
    Rai, A.
    Lavista, M.
    Andrisani, D.
    Laurino, E.
    Canofari, C.
    Pedrollo, E.
    Atzeni, F.
    Sebastiani, D.
    Frediani, B.
    Mosca, M.
    Iannone, F.
    Sebastiani, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 845 - 846
  • [46] REAL-WORLD AUDIT OF PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOSITIS-RELATED INTERSTITIAL LUNG DISEASE IN A EUROPEAN POPULATION
    Loganathan, Aravinthan
    Sturney, Sharon
    Foley, Noeleen
    Hartley, Tom
    Tansley, Sarah
    RHEUMATOLOGY, 2023, 62
  • [47] Efficacy of Antifibrotic Treatments in Patients with Progressive Fibrosing Interstitial Lung Disease
    Sugino, K.
    Ono, H.
    Saito, M.
    Ando, M.
    Tsuboi, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [48] Clinical and molecular analysis of lung cancer associated with fibrosing and diffuse interstitial lung disease
    Heluain, Valentin
    Prevot, Gregoire
    Cabarrou, Bastien
    Calvayrac, Olivier
    Clermont, Estelle
    Didier, Alain
    Milia, Julie
    Mazieres, Julien
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [49] Characteristics of patients with small cell lung cancer in the real-world setting: A systematic review
    Golozar, Asieh
    Faure, Mareva
    Bergamasco, Aurore
    Chen, Kevin
    Arredondo-Bisono, Teigna
    Moride, Yola
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 77 - 78
  • [50] Lung Cancer in Patients with Interstitial Lung Disease: Clinical Characteristics and Impact on Survival
    Hayai, S.
    Taniguchi, H.
    Kondoh, Y.
    Kimura, T.
    Kataoka, K.
    Matsuda, T.
    Yokoyama, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2314 - S2314